Randy Halcomb, Ph.D.
Senior Vice President, Chemistry and Early Development
Randall Halcomb is Senior Vice President of Chemistry and Early Development and co-founder of Terns Pharmaceuticals. Dr. Halcomb brings over 20 years of experience in biopharma and academic life sciences. He previously served as a Director of Medicinal Chemistry at Gilead Sciences where he led programs spanning multiple phases of discovery, from early development and high-throughput screening to lead optimization, which resulted multiple clinical stage candidates. He also contributed to cross-functional initiatives for establishing strategies in new therapeutic areas. Before joining Terns, Dr. Halcomb was Vice President of Chemistry at Igenica Biotherapeutics and Vice President of Medicinal Chemistry at Pliant Therapeutics. Earlier in his career, Dr. Halcomb was an Associate Professor of Chemistry and Biochemistry, with tenure, at the University of Colorado, Boulder.
Dr. Halcomb completed his undergraduate studies at the University of Alabama, earned a Ph.D. from Yale University, and completed postdoctoral studies at the Scripps Research Institute.